Lineage Cell Therapeutics, Inc. - LCTX STOCK NEWS

Lineage Cell Therapeutics (NYSE American: LCTX) has announced the upcoming presentation of results from a Phase 1/2a clinical study of RG6501 (OpRegen) at the 2023 ARVO Annual Meeting in New Orleans, LA, from April 23-27, 2023. The presentation titled 'Exploratory optical coherence tomography analysis in patients with geographic atrophy treated by OpRegen' will be delivered by Eyal Banin, M.D., Ph.D. on April 25, 2023. OpRegen is aimed at treating geographic atrophy secondary to age-related macular degeneration. The therapy is being developed in collaboration with Roche and Genentech and is currently in Phase 2a evaluation.

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) announced it will report its fourth quarter and full year 2022 financial results on March 9, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss these results and provide a business update. Lineage focuses on developing allogeneic cell therapies for unmet medical needs, with several product candidates at various stages of clinical development, targeting markets with billion-dollar opportunities. Their portfolio includes therapies for conditions like age-related macular degeneration and acute spinal cord injuries.

Lineage Cell Therapeutics (LCTX) announced an exclusive option and license agreement with Eterna Therapeutics to develop novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell (iPSC) lines. This collaboration aims to create differentiated cell transplant therapies for central nervous system (CNS) disorders. Eterna's expertise in mRNA-based gene editing will enhance Lineage's capabilities in cell therapy. The agreement allows Lineage to sublicense these gene-edited cell lines for various purposes in CNS-related diseases. Financial terms remain undisclosed.

Lineage Cell Therapeutics (LCTX) has announced progress in its auditory neuronal cell therapy program (ANP1), targeting hearing loss, particularly auditory neuropathy spectrum disorders. The preclinical testing is in collaboration with the University of Michigan, led by Dr. Yehoash Raphael. Lineage's CEO, Brian Culley, highlighted the efficiency of advancing the program with under $1 million from R&D, generating new intellectual property in the process. ANP1 aims to replace missing auditory neurons, offering hope where cochlear implants fail. The company expects significant market potential by addressing a major unmet medical need as nearly 2.5 billion people may face listening impairments by 2050.

Lineage Cell Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming events. CEO Brian Culley will speak at BTIG's Virtual Ophthalmology Day on November 29, 2022, at 12:00pm Eastern, discussing advancements in dry AMD therapies. Following this, Culley will present at Cantor Fitzgerald's Medical & Aesthetic Conference on December 8, 2022, at 1:45pm Eastern, focusing on innovative approaches in ophthalmology. Both conferences aim to explore emerging opportunities in the therapy landscape for degenerative diseases.

Lineage Cell Therapeutics has announced the start of a Phase 2a clinical study for RG6501 (OpRegen), a therapy targeting geographic atrophy (GA) from age-related macular degeneration (AMD). This multicenter study aims to optimize the delivery method and evaluate safety and efficacy in 30 to 60 patients. Notably, previous trials indicated that OpRegen could potentially halt or reverse GA progression. The study's outcomes are anticipated to enhance future trials and may address a significant unmet medical need, as currently, no FDA approved treatments are available for GA.

Lineage Cell Therapeutics (LCTX) announced Jill Howe as CFO, effective November 14, 2022. The company established a new R&D facility and expanded its GMP manufacturing in Israel. As of September 30, 2022, it reported $66.4 million in cash and marketable securities, projected to fund operations into Q3 2024. Lineage's Q3 2022 revenues rose to $3.0 million, driven by collaboration and licensing, while operating expenses decreased to $8.0 million. The net loss attributable to Lineage improved to $6.1 million ($0.04 per share), down from $7.8 million ($0.05 per share) in Q3 2021.

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) will announce its third quarter 2022 financial and operational results on November 10, 2022, after the U.S. market close. Following this, a conference call will be held at 4:30 p.m. ET for discussion and updates. Interested participants can join via phone or a live webcast. Lineage focuses on innovative cell therapies to address unmet medical needs, with several product candidates in development targeting conditions like age-related macular degeneration and spinal cord injuries.

Lineage Cell Therapeutics, Inc. (AMEX: LCTX), a clinical-stage biotech firm, announced a Notice of Allowance from the USPTO for patent No. 16/750,975, covering its oligodendrocyte progenitor cell therapy (OPC1) for spinal cord injury treatment. This patent has a term extending no earlier than 2040. Additionally, the EPO has indicated an intention to grant a patent for preparing retinal pigment epithelium cells. CEO Brian Culley emphasized the strategic importance of these patents for their manufacturing processes and potential to reduce reliance on third-party intellectual property.